Dasanix is the 1st global generic of dasatinib. Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with Chronic Myelogenous Leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.
How does it work in CML ?
Dasatinib (Dasanix) is a tyrosine kinase inhibitor that targets the BCR-ABL protein. Because it was developed after imatinib, it is called a second generation TKI. Like Imatinib, this drug is a pill taken by mouth.
Dasatinib can be used as the first treatment for CML, but it can also be helpful for patients who can’t take Imatinib because of side effects or because Imatinib isn’t working.